EFFICACY AND IMPROVED HEALTH-RELATED QUALITY OF LIFE AFTER 52-WEEKS OF MIRIKIZUMAB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: AN UPDATE FROM A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY

(1) Universitair Ziekenhuizen Leuven,Leuven,Belgium

(2) University California San Diego,La Jolla,United States

(3) Delta Research Partners,Bastrop,United States

(4) Amsterdam University Medical Centers,Amsterdam,Netherlands

(5) Western University,London,Canada

(6) Eli Lilly and Company,Indianapolis,United States



This item was part of the IBD II (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019